文献速递消化道肿瘤与早癌消化内镜

新一代测序检测错配修复缺陷结直肠癌微卫星不稳定性的性能评估

Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
PubMed 文献 · Gastroenterology · 2021-05-13

本研究评估并改进基于NGS的MSI检测方法MSISensor在dMMR结直肠癌中的性能,并开发新算法MSICare。在多个队列中,MSISensor在外显子组水平漏诊16%的MSI/dMMR转移性结直肠癌,而MSICare在C1和C2中检测出100%真实MSI状态,在C4靶向测序中灵敏度99.3%、特异度100%。

要点

  • MSISensor在外显子组水平对dMMR转移性结直肠癌灵敏度仅84%,漏诊4例中3例接受免疫治疗有效。
  • 新算法MSICare在C1和C2中检测100%真实MSI状态,在C3中符合率96.1%。
  • MSICare在靶向NGS条件下灵敏度与特异度保持最优,尤其在MSH6缺陷肿瘤中优于MSISensor。

核心结论

  • MSICare检测MSI的性能至少与参考方法MSI PCR相当,不受缺陷MMR蛋白类型影响,可能成为NGS检测CRC MSI的参考方法,尤其适用于需在ICI处方前准确评估MSI状态的mCRC。

研究设计与样本

  • 事后研究,使用五重PCR和免疫组化中央复核MSI/dMMR状态,采用全外显子组测序评估MSISensor,并开发MSICare算法。
  • 队列C1为前瞻性多中心102例mCRC患者(25例dMMR/MSI,24例接受ICI),来自临床试验NCT02840604和NCT033501260。
  • 队列C2为独立回顾性多中心113例患者(25例mCRC,88例非mCRC,均为dMMR/MSI且未接受ICI)。
  • 队列C3为公开的118例CRC患者(51例dMMR/MSI),来自TCGA。
  • 验证队列C4为回顾性多中心152例新发CRC患者(137例dMMR/MSI),富集MSH6缺陷(n=35)和PMS2缺陷(n=9)肿瘤,使用优化微卫星标记集MSIDIAG进行靶向测序。

主要发现

  • 外显子组水平MSISensor在C1中漏诊16%的MSI/dMMR mCRC(4/25;灵敏度84%;95%CI 63.9%-95.5%),在C2中漏诊32%的mCRC(8/25;灵敏度68%;95%CI 46.5%-85.1%)和9.1%的非mCRC(8/88;灵敏度90.9%;95%CI 82.9%-96%),在C3中漏诊9.8%的CRC(5/51;灵敏度90.2%;95%CI 78.6%-96.7%)。
  • 误诊包括4例接受ICI治疗的mCRC,其中3例截至分析时显示总体缓解且无进展。
  • 外显子组水平MSICare在C1和C2中检测出100%真实MSI状态病例,在C3中MSI状态符合率96.1%。
  • 将WES数据降采样至MSK-IMPACT基因面板后,MSISensor误诊增加(灵敏度72.5%;95%CI 64.2%-79.7%),尤其在MSH6缺陷情况下,而MSICare灵敏度和特异度保持100%。
  • 在C4中使用MSIDIAG靶向NGS后,MSICare灵敏度99.3%(95%CI 96%-100%),特异度100%。

关键数值与推荐

  • MSISensor外显子组水平在C1的MSI/dMMR mCRC中灵敏度84%(95%CI 63.9%-95.5%),在C2的mCRC中灵敏度68%(95%CI 46.5%-85.1%)。
  • MSISensor降采样至MSK-IMPACT面板后灵敏度72.5%(95%CI 64.2%-79.7%)。
  • MSICare在C4靶向测序中灵敏度99.3%(95%CI 96%-100%),特异度100%。

临床怎么用

  • 对于dMMR/mCRC患者,若计划使用ICI,应优先选择MSICare等经过验证的NGS算法检测MSI,避免MSISensor在MSH6缺陷等情况下漏诊。
  • 靶向NGS检测MSI时需注意微卫星标记集的选择,MSIDIAG联合MSICare可提高检测准确性。

局限性

  • 研究为事后分析,部分队列为回顾性设计。
  • C1和C2样本量有限,MSICare在更广泛人群中的性能需进一步前瞻性验证。
  • MSICare在C3中的符合率为96.1%,并非100%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Next-generation sequencing (NGS) was recently approved by the United States Food and Drug Administration to detect microsatellite instability (MSI) arising from defective mismatch repair (dMMR) in patients with metastatic colorectal cancer (mCRC) before treatment with immune checkpoint inhibitors (ICI). In this study, we aimed to evaluate and improve the performance of NGS to identify MSI in CRC, especially dMMR mCRC treated with ICI. METHODS: CRC samples used in this post hoc study were reassessed centrally for MSI and dMMR status using the reference methods of pentaplex polymerase chain reaction and immunohistochemistry. Whole-exome sequencing (WES) was used to evaluate MSISensor, the Food and Drug Administration-approved and NGS-based method for assessment of MSI. This was performed in (1) a prospective, multicenter cohort of 102 patients with mCRC (C1; 25 dMMR/MSI, 24 treated with ICI) from clinical trials NCT02840604 and NCT033501260, (2) an independent retrospective, multicenter cohort of 113 patients (C2; 25 mCRC, 88 non-mCRC, all dMMR/MSI untreated with ICI), and (3) a publicly available series of 118 patients with CRC from The Cancer Genome Atlas (C3; 51 dMMR/MSI). A new NGS-based algorithm, namely MSICare, was developed. Its performance for assessment of MSI was compared with MSISensor in C1, C2, and C3 at the exome level or after downsampling sequencing data to the MSK-IMPACT gene panel. MSICare was validated in an additional retrospective, multicenter cohort (C4) of 152 patients with new CRC (137 dMMR/MSI) enriched in tumors deficient in MSH6 (n = 35) and PMS2 (n = 9) after targeted sequencing of samples with an optimized set of microsatellite markers (MSIDIAG). RESULTS: At the exome level, MSISensor was highly specific but failed to diagnose MSI in 16% of MSI/dMMR mCRC from C1 (4 of 25; sensitivity, 84%; 95% confidence interval [CI], 63.9%-95.5%), 32% of mCRC (8 of 25; sensitivity, 68%; 95% CI, 46.5%-85.1%), and 9.1% of non-mCRC from C2 (8 of 88; sensitivity, 90.9%; 95% CI, 82.9%-96%), and 9.8% of CRC from C3 (5 of 51; sensitivity, 90.2%; 95% CI, 78.6%-96.7%). Misdiagnosis included 4 mCRCs treated with ICI, of which 3 showed an overall response rate without progression at this date. At the exome level, reevaluation of the MSI genomic signal using MSICare detected 100% of cases with true MSI status among C1 and C2. Further validation of MSICare was obtained in CRC tumors from C3, with 96.1% concordance for MSI status. Whereas misdiagnosis with MSISensor even increased when analyzing downsampled WES data from C1 and C2 with microsatellite markers restricted to the MSK-IMPACT gene panel (sensitivity, 72.5%; 95% CI, 64.2%-79.7%), particularly in the MSH6-deficient setting, MSICare sensitivity and specificity remained optimal (100%). Similar results were obtained with MSICare after targeted NGS of tumors from C4 with the optimized microsatellite panel MSIDIAG (sensitivity, 99.3%; 95% CI, 96%-100%; specificity, 100%). CONCLUSIONS: In contrast to MSISensor, the new MSICare test we propose performs at least as efficiently as the reference method, MSI polymerase chain reaction, to detect MSI in CRC regardless of the defective MMR protein under both WES and targeted NGS conditions. We suggest MSICare may rapidly become a reference method for NGS-based testing of MSI in CRC, especially in mCRC, where accurate MSI status is required before the prescription of ICI.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ratovomanana T, Cohen R, Svrcek M, et al. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Gastroenterology. 2021. PMID: 33992635. doi:10.1053/j.gastro.2021.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。